Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 11pembrolizumab 10Oxaliplatin 7Nivolumab 7Irinotecan 7Fluorouracil 7Capecitabine 7durvalumab 6Sorafenib 6Leucovorin 6Cyclophosphamide 6Paclitaxel 5Ipilimumab 5tislelizumab 3poly ICLC 3lenvatinib 3fludarabine 3Sunitinib 3Radiotherapy 3Cisplatin 3Cetuximab 3130-nm albumin-bound paclitaxel 3seocalcitol 2selinexor 2pemigatinib 2futuximab 2fludarabine phosphate 2donafenib 2cemiplimab 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Peptides × Gastrointestinal × Clear all
NCT06564623 2026-05-08

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Recruiting
25 enrolled
Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡